Post/November 11, 2026One-time base editing for sickle cell disease met its goal of a year free of severe crises, Beam saysBeam says its one-time treatment using base editing for sickle cell disease met its pivotal goal of a year free of severe crises; an FDA filing may follow.HNHealthcare News·November 11, 2026
